Rosenberg Matthew Hamilton Sells 947 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Rosenberg Matthew Hamilton decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 34.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,778 shares of the biopharmaceutical company’s stock after selling 947 shares during the period. Rosenberg Matthew Hamilton’s holdings in Gilead Sciences were worth $112,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GILD. Public Employees Retirement Association of Colorado increased its position in shares of Gilead Sciences by 2.8% during the 1st quarter. Public Employees Retirement Association of Colorado now owns 240,155 shares of the biopharmaceutical company’s stock valued at $17,954,000 after purchasing an additional 6,510 shares during the last quarter. APG Asset Management N.V. increased its holdings in Gilead Sciences by 58.4% in the 1st quarter. APG Asset Management N.V. now owns 1,133,202 shares of the biopharmaceutical company’s stock worth $84,718,000 after acquiring an additional 417,845 shares in the last quarter. Procyon Private Wealth Partners LLC increased its holdings in Gilead Sciences by 8.4% in the 1st quarter. Procyon Private Wealth Partners LLC now owns 2,353 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 182 shares in the last quarter. Morgan Stanley increased its holdings in Gilead Sciences by 16.5% in the 1st quarter. Morgan Stanley now owns 6,473,473 shares of the biopharmaceutical company’s stock worth $483,957,000 after acquiring an additional 917,009 shares in the last quarter. Finally, Capital Bank & Trust Co increased its holdings in Gilead Sciences by 7.2% in the 1st quarter. Capital Bank & Trust Co now owns 869,608 shares of the biopharmaceutical company’s stock worth $65,012,000 after acquiring an additional 58,569 shares in the last quarter. Institutional investors own 77.87% of the company’s stock.

Shares of Gilead Sciences stock traded down $0.96 on Friday, reaching $62.00. The company’s stock had a trading volume of 12,307,196 shares, compared to its average volume of 14,747,112. The company has a market capitalization of $77.73 billion, a P/E ratio of -258.32, a PEG ratio of 0.74 and a beta of 0.55. Gilead Sciences, Inc. has a 52-week low of $61.65 and a 52-week high of $85.97. The stock has a 50-day moving average price of $64.31 and a 200-day moving average price of $72.31. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.85 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a dividend yield of 4.39%. The ex-dividend date of this dividend was Monday, September 14th. Gilead Sciences’s payout ratio is 44.30%.

A number of equities research analysts have issued reports on the stock. Citigroup increased their price objective on shares of Gilead Sciences from $78.00 to $80.00 in a report on Monday, August 3rd. SunTrust Banks increased their target price on Gilead Sciences from $73.00 to $74.00 and gave the company a “hold” rating in a research report on Friday, July 31st. BMO Capital Markets increased their target price on Gilead Sciences from $74.00 to $79.00 and gave the company a “market perform” rating in a research report on Wednesday, August 19th. Wells Fargo & Company increased their target price on Gilead Sciences from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 19th. Finally, Oppenheimer raised their price target on Gilead Sciences from $90.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $78.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: Momentum Indicators

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.